| Title : Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy - Furuhashi_2020_Cardiovasc.Diabetol_19_89 |
| Author(s) : Furuhashi M , Sakuma I , Morimoto T , Higashiura Y , Sakai A , Matsumoto M , Sakuma M , Shimabukuro M , Nomiyama T , Arasaki O , Node K , Ueda S |
| Ref : Cardiovasc Diabetol , 19 :89 , 2020 |
| Abstract : Furuhashi_2020_Cardiovasc.Diabetol_19_89 |
| ESTHER : Furuhashi_2020_Cardiovasc.Diabetol_19_89 |
| PubMedSearch : Furuhashi_2020_Cardiovasc.Diabetol_19_89 |
| PubMedID: 32539832 |
Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S (2020)
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
Cardiovasc Diabetol
19 :89
Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S (2020)
Cardiovasc Diabetol
19 :89